- Home
- SBCF vs CORT Comparison
SBCF vs CORT Comparison
Compare SBCF & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBCF | CORT |
|---|---|---|
| Founded | 1926 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2009 | 2001 |
Fundamental Metrics
Financial Performance| Metric | SBCF | CORT |
|---|---|---|
| Price | $30.01 | $33.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $32.00 | ★ $105.20 |
| AVG Volume (30 Days) | 695.3K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 10.56 | N/A |
| EPS | ★ 1.57 | 0.82 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $45.04 | $26.08 |
| Revenue Next Year | $6.30 | $31.04 |
| P/E Ratio | ★ $19.03 | $41.35 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $21.48 | $28.66 |
| 52 Week High | $35.55 | $117.33 |
Technical Indicators
Market Signals| Indicator | SBCF | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 41.82 |
| Support Level | $29.35 | $32.40 |
| Resistance Level | $32.05 | $41.92 |
| Average True Range (ATR) | 0.81 | 1.27 |
| MACD | 0.00 | 0.48 |
| Stochastic Oscillator | 46.79 | 46.70 |
Price Performance
Historical ComparisonAbout SBCF Seacoast Banking Corporation of Florida
Seacoast Banking Corp of Florida is a holding company for Seacoast National Bank. The company provides integrated financial services including commercial and consumer banking, wealth management, and mortgage and insurance services to customers across Florida, and through mobile and online banking solutions. In addition, it provides services such as treasury management, brokerage and credit facilities.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.